2024-10-19 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison and Outperformance**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) over the period considered.  While the S&P 500 generated a cumulative return of 137.88%, LLY achieved a staggering 884.77%. This translates to a  **massive outperformance of 746.89** points, representing **92.67%** of the historical maximum relative outperformance range. 

**2. Recent Price Movements**

LLY's current stock price stands at **917.97**. 
* Over the past 5 days, the stock has traded near its 5-day moving average of **918.87**. 
* Looking at the broader picture, the stock is slightly above its 20-day moving average of **907.78** and its 60-day moving average of **900.17**. This suggests potential upward momentum in the short to medium term.

**3. Technical Indicators**

* **RSI (Relative Strength Index):**  65.14, indicating the stock is currently in the overbought territory. This suggests that a short-term pullback might be possible.
* **PPO (Percentage Price Oscillator):** 0.21, showing a positive price momentum.
* **Delta_Previous_Relative_Divergence:** -1.59, indicating a slight decrease in relative outperformance over the past 20 days.
* **Expected Return:** 35.1%, suggesting potential long-term outperformance compared to the S&P 500.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2023-05-09 | 1.96 | 8.31 B$ |

**Recent Earnings Analysis:**

* **Most Recent (2024-08-08):**  While specific analyst expectations for this quarter aren't provided,  the reported EPS of 3.29 and revenue of 11.30 B$ show a strong performance, demonstrating sustained growth momentum. 
* **Overall Trend:** Eli Lilly's revenue growth has been consistent, showcasing its strong market position and potential for continued expansion. 

**5. News and Recent Issues**

**Recent Market Outlook:** Eli Lilly's stock price has been on an upward trajectory due to various factors, including strong drug launches, robust pipeline development, and increasing demand for its products. The company's focus on innovative therapies and expanding global reach continues to drive growth.

**Analyst Opinions:**  Many analysts remain optimistic about Eli Lilly's future performance, citing its robust pipeline, strong market position, and consistent financial performance. 

**Performance Highlights:**  Recent news highlights Eli Lilly's success in launching new diabetes medications and its ongoing research in Alzheimer's disease.  

**6.  Overall Analysis**

Eli Lilly and Co (LLY) is a financially strong company with a strong track record of outperformance.  The recent earnings performance has been impressive and its robust drug pipeline, coupled with a growing global presence,  suggest continued potential for growth. While the stock is currently in overbought territory, the long-term prospects remain positive, indicating a solid investment opportunity. 

**7. English Report**

Eli Lilly and Co (LLY) is a pharmaceutical company specializing in the development and manufacturing of pharmaceutical and biotechnological products. The company's core areas include diabetes, oncology, immunology, neurology, and cardiovascular diseases. 


This report analyzes the company's recent performance, technical indicators, and market outlook. Here are the key findings:

* **Outperformance:** LLY has significantly outperformed the S&P 500 (VOO) over the period, displaying a 92.67% relative outperformance compared to the benchmark.
* **Price Movement:**  The stock is currently trading slightly above its 20 and 60-day moving averages, suggesting potential upward momentum. 
* **Technical Indicators:** The stock is currently in overbought territory, but positive price momentum is observed.
* **Earnings:**  The company demonstrated strong recent earnings performance, indicating continued growth momentum.
* **Outlook:** Analysts remain optimistic about Eli Lilly's future performance, citing robust pipeline, strong market position, and consistent financial performance. 

Overall, Eli Lilly and Co presents a compelling investment case, backed by its strong performance, robust pipeline, and positive market outlook. However, investors should acknowledge the potential short-term pullback due to overbought conditions. 
